MedPath

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFECT OF 52 WEEKS TREATMENT WITH LAF237 50 MG BID TO METFORMIN UP TO 1000 MG BID IN DRUG NAIVE PATIENTS WITH TYPE 2 DIABETES

Conditions
MONOTHERAPY TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
MedDRA version: 6.1Level: PTClassification code 10012601
Registration Number
EUCTR2004-000376-14-IT
Lead Sponsor
OVARTIS FARMA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
660
Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: ;Secondary Objective: ;Primary end point(s):
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath